TriangleNCT02765854 · OUTCOME
Time to Treatment Failure
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEAN
- Unit
- Months
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- Up to 30 months
What was measured
Kaplan-Meier curves will be used for the time to treatment failure according to the Arm of treatment utilized. Kaplan-Meyer curve analysis was performed to evaluate the time to treatment failure comparison.
Groups in this outcome
Arm B (Ixazomib and Dexamethasone)
MUTATED NFKB2 REARRANGEMENT: Patients receive ixazomib and dexamethasone as in arm A. Dexamethasone: Given PO Ixazomib: Given PO
Arm C (Ixazomib, Dexamethasone, Lenalidomide)
MUTATED NFKB2 REARRANGEMENT: Patients receive ixazomib and dexamethasone as in arm A and lenalidomide PO daily on days 1-21. Dexamethasone: Given PO Ixazomib: Given PO Lenalidomide: Given PO
Arm A (Ixazomib and Dexamethasone)
UNMUTATED NFKB2 REARRANGEMENT: Patients receive ixazomib and dexamethasone. Dexamethasone: Given PO Ixazomib: Given PO
| Group | Source count |
|---|---|
| Arm B (Ixazomib and Dexamethasone) | 22 |
| Arm C (Ixazomib, Dexamethasone, Lenalidomide) | 21 |
| Arm A (Ixazomib and Dexamethasone) | 27 |
Reported measurements
6 Months
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Arm B (Ixazomib and Dexamethasone) | 0.495 | Not reported | 0.259 | 0.693 | Not reported |
| Arm C (Ixazomib, Dexamethasone, Lenalidomide) | 0.683 | Not reported | 0.419 | 0.847 | Not reported |
| Arm A (Ixazomib and Dexamethasone) | 0.729 | Not reported | 0.512 | 0.861 | Not reported |
12 Months
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Arm B (Ixazomib and Dexamethasone) | 0.353 | Not reported | 0.142 | 0.575 | Not reported |
| Arm C (Ixazomib, Dexamethasone, Lenalidomide) | 0.312 | Not reported | 0.103 | 0.551 | Not reported |
| Arm A (Ixazomib and Dexamethasone) | 0.729 | Not reported | 0.512 | 0.861 | Not reported |
18 Months
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Arm B (Ixazomib and Dexamethasone) | 0.283 | Not reported | 0.095 | 0.508 | Not reported |
| Arm C (Ixazomib, Dexamethasone, Lenalidomide) | 0.312 | Not reported | 0.103 | 0.551 | Not reported |
| Arm A (Ixazomib and Dexamethasone) | 0.663 | Not reported | 0.425 | 0.821 | Not reported |
24 Months
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Arm B (Ixazomib and Dexamethasone) | 0.141 | Not reported | 0.024 | 0.357 | Not reported |
| Arm C (Ixazomib, Dexamethasone, Lenalidomide) | 0.156 | Not reported | 0.026 | 0.388 | Not reported |
| Arm A (Ixazomib and Dexamethasone) | 0.505 | Not reported | 0.249 | 0.715 | Not reported |
30 Months
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Arm B (Ixazomib and Dexamethasone) | 0.141 | Not reported | 0.024 | 0.357 | Not reported |
| Arm C (Ixazomib, Dexamethasone, Lenalidomide) | 0.078 | Not reported | 0.005 | 0.294 | Not reported |
| Arm A (Ixazomib and Dexamethasone) | 0.421 | Not reported | 0.176 | 0.65 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 0.259
- upper Limit
- 0.693
- value
- 0.495
- group Id
- OG001
- lower Limit
- 0.419
- upper Limit
- 0.847
- value
- 0.683
- group Id
- OG002
- lower Limit
- 0.512
- upper Limit
- 0.861
- value
- 0.729
- title
- 6 Months
- categories
- measurements
- group Id
- OG000
- lower Limit
- 0.142
- upper Limit
- 0.575
- value
- 0.353
- group Id
- OG001
- lower Limit
- 0.103
- upper Limit
- 0.551
- value
- 0.312
- group Id
- OG002
- lower Limit
- 0.512
- upper Limit
- 0.861
- value
- 0.729
- title
- 12 Months
- categories
- measurements
- group Id
- OG000
- lower Limit
- 0.095
- upper Limit
- 0.508
- value
- 0.283
- group Id
- OG001
- lower Limit
- 0.103
- upper Limit
- 0.551
- value
- 0.312
- group Id
- OG002
- lower Limit
- 0.425
- upper Limit
- 0.821
- value
- 0.663
- title
- 18 Months
- categories
- measurements
- group Id
- OG000
- lower Limit
- 0.024
- upper Limit
- 0.357
- value
- 0.141
- group Id
- OG001
- lower Limit
- 0.026
- upper Limit
- 0.388
- value
- 0.156
- group Id
- OG002
- lower Limit
- 0.249
- upper Limit
- 0.715
- value
- 0.505
- title
- 24 Months
- categories
- measurements
- group Id
- OG000
- lower Limit
- 0.024
- upper Limit
- 0.357
- value
- 0.141
- group Id
- OG001
- lower Limit
- 0.005
- upper Limit
- 0.294
- value
- 0.078
- group Id
- OG002
- lower Limit
- 0.176
- upper Limit
- 0.65
- value
- 0.421
- title
- 30 Months
- denoms
- counts
- group Id
- OG000
- value
- 22
- group Id
- OG001
- value
- 21
- group Id
- OG002
- value
- 27
- units
- Participants
- description
- Kaplan-Meier curves will be used for the time to treatment failure according to the Arm of treatment utilized. Kaplan-Meyer curve analysis was performed to evaluate the time to treatment failure comparison.
- dispersion Type
- 95% Confidence Interval
- groups
- description
- MUTATED NFKB2 REARRANGEMENT: Patients receive ixazomib and dexamethasone as in arm A. Dexamethasone: Given PO Ixazomib: Given PO
- id
- OG000
- title
- Arm B (Ixazomib and Dexamethasone)
- description
- MUTATED NFKB2 REARRANGEMENT: Patients receive ixazomib and dexamethasone as in arm A and lenalidomide PO daily on days 1-21. Dexamethasone: Given PO Ixazomib: Given PO Lenalidomide: Given PO
- id
- OG001
- title
- Arm C (Ixazomib, Dexamethasone, Lenalidomide)
- description
- UNMUTATED NFKB2 REARRANGEMENT: Patients receive ixazomib and dexamethasone. Dexamethasone: Given PO Ixazomib: Given PO
- id
- OG002
- title
- Arm A (Ixazomib and Dexamethasone)
- param Type
- MEAN
- reporting Status
- POSTED
- time Frame
- Up to 30 months
- title
- Time to Treatment Failure
- type
- SECONDARY
- unit Of Measure
- Months
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice